678 results about "CHD - Coronary heart disease" patented technology

The present invention relates to traditional Chinese medicine for treating coronary heart disease and stenocardia is made from (by wt.%) salvia root 50-97%, notoginseng 2-48% and borneol 0.2-3%, in which the salvia root and notoginseng and hot extracted with water, then filtering, concentrating, alcohol precipitating, standing still, recovering ethyl alcohol, concentrating, into extractum, further blended with borneol and adjuvant polyglycol-6000 to form into product.

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

The invented healthy edible salt is prepared by mixing with sodium chloride, various amino acid, peptide substance, vitamin B family, polysaccharide, or chitin, antioxidant, nucleic acid seasoning, potassium chloride, calcium salt, magnesium salt, selenium salt, and potassium iodide. It can effectively prevent various diseases, also can prevent osteoporosis, cancer, diabetes, dysinsulinosis, lithiasis, coronary heart disease, senile dementia, bark farus etc. it also possesses the functions of antisenility, antifatigue, antidepression, improving immune power, promoting growth etc.

The invention relates to novel compounds as LXR receptor stimulating agents and a medicament composition containing the compounds or pharmaceutically acceptable salt thereof and also relates to a method for preparing the compounds and the medicament composition thereof. The invention discloses application of the compounds as pharmacological active substances, in particular application in treating cardiovascular diseases such as hypertension, hyperlipemia, hypercholesterolemia, atherosclerosis and coronary heart disease, as well as inflammation, adiposis, diabetes, metabolic syndrome and the like.

The invention relates to an intravascular ultrasound image and intravascular-OCT image fusing method. The method includes the following steps of (a) image retrieval, wherein for intravascular ultrasound (IVUS) images and intravascular (IV)-OCT images collected at the same position on a blood vessel section, a frame of IV-OCT image is taken as a reference image, and an image to be registered is selected from the n frames of IVUS images collected from the point; (b) IVUS image and IV-OCT image registration; (c) IVUS image and IV-OCT image fusion. IV-OCT image data and IVUS image data of the same blood vessel section are fused, the advantage of high tissue penetrating power of IVUS imaging and the advantage of high resolution of IV-OCT imaging are brought into full play, more comprehensive description of blood vessel walls and atherosclerotic plaques is obtained, and a reliable basis is provided for research on the coronary heart disease and the like.

A substantially purified substance having the properties of a bacterial microcin methionine analog, methionine synthesis inhibitor, tRNA-methionine synthase inhibitors or methionine competitive inhibitor capable of inhibiting tumor cell growth without inhibiting the growth of normal cells or treating neoplastic diseases, and may be used alone or in combination with other anti-cancer agents. The purified substance may also have anti-hyperhomocysteineuria and/or anti-infective properties, such as antifungal activity. The purified substance can be safely administered to animals including humans for the treatment of neoplastic, hyperhomocysteinemia and/or infectious diseases for the treatment of those diseases.

The invention provides mulberry leaf and tartary buckwheat fine dried noodles. The mulberry leaf and tartary buckwheat fine dried noodles are prepared from 55-70 parts by mass of tartary buckwheat flour, 15-30 parts by mass of wheat gluten, 5-15 parts by mass of high gluten wheat flour, 3-10 parts by mass of mulberry leaf powder, 0.5-1.5 parts by mass of edible salt, 0.3-0.7 part by mass of sodium carbonate, 0.1-0.3 part by mass of konjac gum, 0.1-0.3 part by mass of xanthan gum and 35-42 parts by mass of drinking water. A preparation method of the mulberry leaf and tartary buckwheat fine dried noodles comprises the processes of preparation of a noodle improver solution, dough kneading, ripening, tabletting, drying, packaging and the like. The products are unique in formula, have excellent taste, are rich in nutrients, have prominent health care functions and are suitable for all kinds of people to eat, especially patients with constipation, obesity, diabetes mellitus, hypertension and coronary heart diseases.

The present invention relates to compounds of phosphonic acid-containing T3 mimetics and monoesters thereof, stereoisomers, pharmaceutically acceptable salts, co-crystals, and prodrugs thereof and pharmaceutically acceptable salts and co-crystals of the prodrugs, as well as their preparation and uses for preventing and/or treating metabolic diseases such as obesity, NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, metabolic syndrome x and diabetes.

The invention relates to the field of medical biotechnology, in particular to a making method for coronary heart disease and apoplexy risk diagnosis kit. The kit is used for quantitative analysis of Lp-PLA2 level in human plasma or blood serum by enzyme linked immunosorbent assay, so as to prevent heart disease and apoplexy.

The invention discloses a PEGylated scutellarin compound and a preparation method thereof. The PEGylated scutellarin compound is as the shown formula (IV) and the PEGylated scutellarin compound can be applied to preparing medicaments applied to treating cerebral thrombosis, cerebral infarction, cerebral apoplexy, sequelaes caused by cerebral apoplexy, coronary heart disease or angina. Compared with the original scutellarin compound, the water solubility of the scutellarin compound is increased obviously; simultaneously, pharmacodynamics experiment on the mice model of cerebral ischemia-reperfusion shows that: compared with the original medicament, the biological activity of the scutellarin promedicament is strengthened obviously.

The invention relates to a method for determining fingerprint spectrum of traditional Chinese medicine for treating coronary heart disease. The method comprises the following steps: preparing a test solution, preparing a reference solution, and carrying out gradient elution under the chromatographic conditions that an Agilent ZORBAX Extend C18 chromatographic column is used as a filling agent, a mobile phase A is methanol and a mobile phase B is 0.4% phosphoric acid water solution; determining under conditions that the flow velocity is at 1.0ml/min, the column temperature is at 35 DEG C and the detection wavelength is 230-240nm, thus obtaining the fingerprint spectrum of traditional Chinese medicine. The method has the characteristics of being simple and convenient, good in reproducibility, more in characteristic peaks, accurate and reliable, and the like, and the quality of the traditional Chinese medicine preparation can be controlled effectively by the established fingerprint spectrum.

The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, coronary heart disease, thrombosis, and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.

The invention relates to a molecular probe in a medical imaging diagnostic reagent, and in particular relates to a preparation method of an MRI/PET bimodal molecular imaging probe for an atherosclerotic vulnerable plaque. According to the probe, molecular imaging can be performed on a new vessel of the atherosclerotic vulnerable plaque, and early warning of an unstable plaque is realized so as to provide a favorable new molecular imaging technology for early diagnosis and prevention of the coronary heart disease and reduction of serious cardiovascular event risk. The preparation method comprises the following step: chemically synthesizing a new vessel specific MRI/PET bimodal molecular imaging probe 68Ga-GEBP11-DMSA (dimercaptosuccinic acid)-MNPs through condensation reaction and chelating reaction by taking GEBP11 short peptide as a targeting tool and DMSA modified magnetic Fe3O4 nanoparticles (DMSA-MNPs) as carriers.

The invention relates to health-care rice vinegar and a preparation process thereof. The invention belongs to the technical field of processing of condiments and particularly relates to health-care rice vinegar prepared from millet serving as a main raw material and traditional Chinese medicinal materials. The health-care rice vinegar is prepared from the main raw material comprising millet, traditional Chinese medicinal materials comprising hawthorn, dark plum fruit, semen cassia, lotus leaf, oriental wormwood, oolong, lucid ganoderma, immature bitter orange, aloe, peach kernel, ginger and yam, and auxiliary materials comprising wheat koji, bran, cavings and salt. The health-care rice vinegar has the advantages of 1, comprehensively adjusting lipid metabolism, obviously reducing hyperlipaemia, reducing serum total cholesterol, triglyceride and low-density lipoprotein, obviously increasing high-density lipoprotein and degrading atherosclerotic plaques; 2, reducing blood viscosity, obviously inhibiting platelet abnormal coagulation, improving hemodynamic indexes, promoting blood circulation, avoiding thrombus and effectively preventing apoplexia; and 3, dredging blood vessels, improving blood supply microcirculation, improving brain and heart blood supply insufficiency, inhibiting atherosclerosis and effectively preventing coronary heart disease.

The invention discloses a next generation sequencing based coronary heart disease genetic risk evaluation method. Particularly, the invention relates to screening of coronary heart disease genetic risk loci and establishment of a coronary heart disease genetic risk evaluation model based on the risk loci. Depending on the model, an individual genome is subjected to targeted sequencing to finally obtain coronary heart disease genetic risk of an individual.

The invention provides methods for diagnosing coronary heart disease in a subject in need thereof comprising administering an admixture comprising CO2 to a subject to reach a predetermined PaCO2 in the subject to induce hyperemia, monitoring vascular reactivity in the subject and diagnosing the presence or absence of coronary heart disease in the subject, wherein decreased vascular reactivity in the subject compared to a control subject is indicative of coronary heart disease. The invention also provides methods for increasing sensitivity and specificity of BOLD MRI.

The present invention relates to novel thyroid receptor ligands and, more particularly, relates to malonamic acids and derivatives thereof of Formula I, which are useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss. The present invention also provides methods, pharmaceutical compositions and kits for treating such diseases and disorders.